Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
Solicitation from Department of Health and Human Services.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 27 days
Notice details
- Notice type
- Solicitation
- Solicitation number
- 75A50126R00001_RFP_NPIVS_27
- Product/service code
- AN12
- Place of performance
- Washington, District of Columbia
- Posted
- Sep 12, 2026
- Response deadline
- Nov 20, 2026
- Source
- SAM.gov
Description
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Similar open notices
- Quantitative Analysis of Longitudinal MR ImagesClosing in 16 days
- Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)Closing in 37 days
- Pre-Clinical Models of Infectious DiseasesClosing in 44 days
- UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)Closing in 53 days
- ARPA-H Emerging Health Innovators (EHI) InitiativeClosing in 109 days
Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Nov 20, 2026. That is 27 days after the data date.
What NAICS code applies?
NAICS 541714, Research and Development in Biotechnology (except Nanobiotechnology).
Which agency issued this notice?
Department of Health and Human Services.
Where is the official notice?
The link under Official notice opens the source listing.